About Javeri Equity Derivatives Mutual Funds IPO Corporate Info Research Contact Us
Corporate Info
Smart Quotes
Company Background
Board of Directors
Balance Sheet
Profit & Loss
Peer Comparison
Cash Flow
Shareholdings Pattern
Quarterly Results
Share Price
Deliverable Volume
Historical Volume
MF Holdings
Financial Ratios
Directors Report
Price Charts
Notes Of Account
Management Discussion
Beta Analysis
Board Meetings
Corporate Announcements
Book Closure
Record Date
Bonus
Company News
Bulk Deals
Block Deals
Monthly High/low
Dividend Details
Bulk Deals
Insider Trading
Advanced Chart
HOME   >  CORPORATE INFO >  BOARD MEETINGS
Board Meetings      
Indrayani Biotech Ltd.
Source DateBoard Meeting DateDetails
23-Feb-2026 26-Feb-2026 Quarterly Results
05-Dec-2025 11-Dec-2025 Quarterly Results
13-Nov-2025 14-Nov-2025 Quarterly Results
26-Aug-2025 30-Aug-2025 Inter alia, to consider and approve:- 1.Notice of the 33rd Annual General Meeting of the company. 2.Disinvestment from Material Subsidiary - Dindigul Farm Product Limited. 3.Reclassification from Promoter status to Public shareholder status at Dindigul Farm Product Limited. 4.Rescindment Of Resolution Passed at the 32nd Annual General Meeting for Increasing the Authorized Share Capital. 5.Increase of Authorised share capital of the Company from Rs.65 crores to Rs.85 crores comprising 8.50 crores equity shares of Rs. 10/- each (Eight Crores and Fifty Lakhs) and consequential amendment of the capital clause in the Memorandum of Association of the Company. 6.Appointment of Mr. Swaminathan (DIN: 02481041) as Whole-Time Director. 7.Appointment of Mr. Singarababu Indirakumar (DIN: 00892351) as Whole-Time Director.
11-Aug-2025 14-Aug-2025 Quarterly Results
09-Jun-2025 12-Jun-2025 Audited Results
28-May-2025 09-Jun-2025 Audited Results(Cancelled) (Cancelled)
27-Mar-2025 03-Apr-2025 Right Issue of Equity Shares
27-Feb-2025 27-Feb-2025 Quarterly Results
10-Feb-2025 14-Feb-2025 Quarterly Results
11-Nov-2024 14-Nov-2024 Quarterly Results & Right Issue of Equity Shares
08-Aug-2024 14-Aug-2024 Quarterly Results
24-Jul-2024 27-Jul-2024 Inter alia, to consider and approve the following items of business:- 1. To approve the increase and reclassification of authorized share capital of the company subject to the approval of the shareholders. 2. To increase the limit of investment in the total paid up capital of the Company by foreign portfolio investors, foreign institutional investors and non-resident Indians subject to the approval of the shareholders. 3. To consider and approve material related party transactions between the Company and subsidiaries subject to the approval of the shareholders. 4. To consider and approve Directors? report and annexures thereon. 5. To take note of the Secretarial audit report 6. To fix the date, time, venue and mode of 32ndAnnual General Meeting of the Company and approve the draft Notice for convening the said General Meeting. 7. To appoint the Scrutinizer for 32nd Annual General Meeting of the Company. 8. Other business matters.
23-May-2024 30-May-2024 Audited Results
05-Feb-2024 10-Feb-2024 Quarterly Results
08-Jan-2024 10-Jan-2024 Increase in Authorised Capital & Inter alia, to transact the following business: 1. To consider the proposal for increasing the authorized share capital subject to the shareholders? approval. 2. To consider and approve the conversion of unsecured loans into equity under Section 62(3) of the Companies Act, 2013 subject to the shareholders? approval. 3. Any other business with the permission of the Chair.
09-Nov-2023 14-Nov-2023 Quarterly Results
27-Oct-2023 01-Nov-2023 Dividend on Preference Shares & Inter alia, to consider and approve:- 1. To recommend Payment of dividend on 12% Compulsorily Convertible Preference Shares. 2. To consider and approve the allotment of Equity shares by conversion of Compulsorily Convertible Preference Shares subject to lock in period of 6 months. 3. To consider and approve the conversion of Warrants into Equity Shares subject to lock in period of 6 months. 4. Any other matter with the permission of the chair.
07-Aug-2023 11-Aug-2023 Quarterly Results
07-Jun-2023 14-Jun-2023 Audited Results
Page 1 of 6
Prev || Next
Disclaimer | Privacy Policy | Grievance | FAQ | Sitemap | Client Registration | Useful Links| Anti Money Laundering | Inactive Client Policy | Scores
Smart ODR Portal | Vernacular Kyc | Advisory For Investors | Investor Adviser | Filing complaints on SCORES - Easy & quick | Policy on PMLA | Publishing of investor charter information | Annexure A – Investor charter of brokers | Annexure A – Investor charter of DP | Annexure B –Linked content for information to charter for DP | Annexure B & C (investor complaint data) broker & DP | Investor Charter & Complaints | Advisory-KYC Compliance | E-Voting NSE | E-Voting BSE | Details of Client Bank Accounts | Risk Disclosure | NSE FO Risk disclosure | Details of Research Analyst | UPI QR CODE
SEBI Regn. No.: INB010997431 (BSE), INB230997430 (NSE)
Copyright 2008 Javeri Fiscal Services Ltd.
Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.
CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.
Source: Click Here.